Atherotech Closed Permanently

Dear Friends of Atherotech,

We regret to inform you that Atherotech will be closing permanently on February [28], 2016. As a result, effective immediately, we will no longer be accepting samples or performing tests.

Over the last few years, Atherotech has worked hard to overcome numerous business challenges that resulted from adverse changes in the regulatory environment, increased pressure from commercial insurance payors and continued compression of profit margins. During this period, the Company’s management team and Board of Directors have worked tirelessly to restructure the business in a constructive manner that would allow us to continue providing service to the thousands of patients and physicians who rely on us to diagnose and assess cardiovascular risk each day. Every step of the way, the dedication of our employees has been an inspiration.

Unfortunately, despite our best efforts and the willingness of several parties to take difficult steps to overcome our challenges, we have been unsuccessful in convincing our lenders to cooperate so that we can extend the financing necessary to allow us to continue operations. As a result, we are now forced to close permanently.

We thank you all for being part of the Atherotech story and appreciate your steadfast support of our Company during the past 20 years.

Best regards,

Jim McClintic

Chief Executive Officer

 

ATHEROTECH DIAGNOSTICS OPENS NEW PATIENT SERVICE CENTER IN SAN ANTONIO

Atherotech Diagnostics Opens New Patient Service Center in SAN ANTONIO

Access to Comprehensive Diagnostic Tests Helps Patients, Physicians

Gain a Better Picture of Overall Heart Health

Birmingham, Alabama, June 11, 2015 ― Atherotech Diagnostics Lab, a leading clinical reference laboratory specializing in cardiometabolic testing and disease management solutions, has opened a new Patient Service Center in San Antonio, Texas. The new center will provide blood draws in order to facilitate a number of Atherotech’s diagnostic tests. These tests help physicians gain the most complete picture of their patients’ overall health, such as cardiometabolic risk assessment, hormone and genetic testing. One key test offering at the new Patient Service Center will be Atherotech’s proprietary VAP®+ Lipid Panel, the most accurate cholesterol test available. Through a single blood draw, physicians may assess a person’s cardiometabolic risk in order to prevent heart attack, stroke and other cardiovascular events.

“We are thrilled to announce the opening of the new Atherotech Patient Service Center in San Antonio, Texas,” said Jim McClintic, President and Chief Executive Officer of Atherotech. “Having the opportunity to service patients in the area with one or more of our unique diagnostic tests further supports our company’s commitment to improving the lives of those living with, or at risk for, cardiovascular disease.”

In addition to its vast portfolio of tests, Atherotech also offers a unique counseling service called Our Healthy Heart™ to recipients of the VAP test. This service connects patients with a Clinical Health Coach to develop nutrition and exercise plans that help them maintain their goals of living longer, healthier lives.

The Atherotech Patient Service Center will be located at 7434 Louis Pasteur Drive, Suite 109, San Antonio, Texas, 78229. For more information or to schedule an appointment, visit www.Atherotech.com/location or call 866-827-8378.

 

About Atherotech and the VAP®+ Lipid Panel

Atherotech Diagnostics Lab is a leading clinical reference laboratory specializing in cardiometabolic testing and disease management solutions. Atherotech’s proprietary VAP®+ Lipid Panel enables clinicians to accurately stratify a patient’s cardiovascular risk and deliver personalized treatment strategies to improve health outcomes. For more information, please visit www.Atherotech.com or call 1-866-VAP-TEST.

 

For information on the VAP+ Lipid Panel and Atherotech Diagnostics Lab, visit www.Atherotech.com or call 877-901-8510. Atherotech is on Twitter at www.twitter.com/Atherotech, on Facebook at www.facebook.com/Atherotech, and broadcasting at www.YouTube.com/user/VAPatherotech.

 

San Antonio_Patient Service Center Opening Press Release_6-10-15

ATHEROTECH DIAGNOSTICS OPENS NEW PATIENT SERVICE CENTER IN ALBUQUERQUE

 

Atherotech Diagnostics Opens New Patient Service Center in Albuquerque

Access to Comprehensive Diagnostic Tests Helps Patients, Physicians

Gain a Better Picture of Overall Heart Health

Birmingham, Alabama, June 11, 2015 ― Atherotech Diagnostics Lab, a leading clinical reference laboratory specializing in cardiometabolic testing and disease management solutions, has opened a new Patient Service Center in Albuquerque, New Mexico. The new center will provide blood draws in order to facilitate a number of Atherotech’s diagnostic tests. These tests help physicians gain the most complete picture of their patients’ overall health, such as cardiometabolic risk assessment, hormone and genetic testing. One key test offering at the new Patient Service Center will be Atherotech’s proprietary VAP®+ Lipid Panel, the most accurate cholesterol test available. Through a single blood draw, physicians may assess a person’s cardiometabolic risk in order to prevent heart attack, stroke and other cardiovascular events.

“We are thrilled to announce the opening of the new Atherotech Patient Service Center in Albuquerque, New Mexico,” said Jim McClintic, President and Chief Executive Officer of Atherotech. “Having the opportunity to service patients in the area with one or more of our unique diagnostic tests further supports our company’s commitment to improving the lives of those living with, or at risk for, cardiovascular disease.”

In addition to its vast portfolio of tests, Atherotech also offers a unique counseling service called Our Healthy Heart™ to recipients of the VAP test. This service connects patients with a Clinical Health Coach to develop nutrition and exercise plans that help them maintain their goals of living longer, healthier lives.

The Atherotech Patient Service Center will be located at 6000 Uptown Boulevard NE, Suite 335, Albuquerque, New Mexico, 87110. For more information or to schedule an appointment, visit www.Atherotech.com/location or call 866-827-8378.

 

About Atherotech and the VAP®+ Lipid Panel

Atherotech Diagnostics Lab is a leading clinical reference laboratory specializing in cardiometabolic testing and disease management solutions. Atherotech’s proprietary VAP®+ Lipid Panel enables clinicians to accurately stratify a patient’s cardiovascular risk and deliver personalized treatment strategies to improve health outcomes. For more information, please visit www.Atherotech.com or call 1-866-VAP-TEST.

 

For information on the VAP+ Lipid Panel and Atherotech Diagnostics Lab, visit www.Atherotech.com or call 877-901-8510. Atherotech is on Twitter at www.twitter.com/Atherotech, on Facebook at www.facebook.com/Atherotech, and broadcasting at www.YouTube.com/user/VAPatherotech.

 

Albuquerque_Patient Service Center Opening Press Release_6-10-15

VLP™ LDLp shows comparable results to NMR lipoprofile® in determining risk of coronary heart disease at 2014 National Lipid Association Scientific Sessions

ORLANDO, FL – Data from a comparison study using the Vertical Lipoprotein Particle™ (VLP) and Nuclear Magnetic Resonance (NMR) Lipoprofile® showed that the VLP™ compared well with the NMR, further demonstrating the benefit of new testing methods for determining a patient’s risk for coronary heart disease (CHD).  Continue reading “VLP™ LDLp shows comparable results to NMR lipoprofile® in determining risk of coronary heart disease at 2014 National Lipid Association Scientific Sessions”

Data showing benefit of the VAP Lipid Panel presented via 3 poster presentations at 2014 American College of Cardiology Scientific Sessions

WASHINGTON, D.C. – Data presented today from two meta-analyses using the Atherotech Vertical Auto Profile (VAP®) Lipid Panel showed the impact high-density lipoprotein (HDL) cholesterol and remnant lipoprotein (RLP) cholesterol have on determining a patient’s risk for hard coronary heart disease (CHD) endpoints, such as myocardial infarction or coronary death. Each analysis examined men and women without prevalent CHD enrolled in both the Framingham Offspring and Jackson Heart studies over eight years. In both studies, HDL, the “good” cholesterol in the body and RLP, similar to the “bad” cholesterol in the body (low-density lipoprotein, or LDL) – levels were measured by the VAP® Lipid Panel, the most accurate and comprehensive lipid profile available to assess cardiometabolic risk. While previous study findings have shown the link between HDL and CHD, results from the meta-analyses determined that HDL subfractions, specifically HDL3, were much more predictive in assessing and reducing a patient’s risk for CHD, while RLP cholesterol was associated with increasing a patient’s risk. Data from both studies were presented via poster today at the 2014 Annual Meeting of the American College of Cardiology (ACC) in Washington, D.C.


“With a significant relationship between HDL, RLP and hard CHD events, these findings are a critical step forward in helping physicians develop a better understanding of the relationship between lipoproteins and cardiovascular risk,” said Dr. Steven R. Jones, investigator and Director of Inpatient Cardiology at Johns Hopkins Hospital as well as faculty of the Johns Hopkins Ciccarone Center for the Prevention of Heart Disease in Baltimore. “Using a comprehensive lipid test, such as the VAP® Lipid Panel, may help physicians paint the best picture of a patient’s overall risk.”


The first meta-analysis examined HDL cholesterol subfractions, specifically HDL2 (cholesterol removal) and HDL3 (cholesterol distribution), and the risk for CHD. HDL2 is responsible for removing cholesterol from the bloodstream while HDL3 is responsible for the distribution of cholesterol. In previous studies throughout the world, HDL cholesterol has been negatively correlated with risk for CHD; however, the relationship between HDL subfractions and CHD is much more controversial. Findings from the study revealed a significant correlation between HDL cholesterol as well as HDL3 cholesterol risk for incident hard CHD events. For each tertile increase in HDL cholesterol and HDL3 cholesterol, there was a 25 percent and 28 percent reduction in risk for hard CHD, respectively. Despite this connection, HDL2 cholesterol did not achieve statistically significant results related to reducing risk of CHD.


The second meta-analysis reviewed RLP on hard CHD events. Remnants are precursors to LDL and can be elevated if there is impaired triglyceride lipid breakdown as observed in patients with metabolic syndrome and diabetes. Results showed that LDL cholesterol and non-HDL cholesterol demonstrated significant relationships with hard CHD risk. In addition, intermediate-density lipoprotein (IDL), which enables fat and cholesterol to move within the bloodstream, and RLP cholesterol were also highly correlated with increasing risk for hard CHD. For each tertile rise in IDL cholesterol and RLP cholesterol, there was a 41 percent and 37 percent increase in risk for hard CHD, respectively.


Atherotech also presented additional data from The Jackson Heart study via poster on March 29, 2014. For more information on Atherotech or the VAP® Lipid Panel, visit www.Atherotech.com.


About Atherotech Diagnostics Lab & the VAP®+ Lipid Panel Atherotech Diagnostics Lab is a leading clinical reference laboratory specializing in cardiometabolic testing and disease management solutions. Atherotech’s proprietary and comprehensive VAP®+ Lipid Panel enables clinicians to accurately stratify a patient’s cardiovascular risk and deliver personalized treatment strategies to improve health outcomes. The Vertical Auto Profile (VAP+) technology reveals residual cardiometabolic risk as recommended in the NCEP ATP III, ADA/ACC Joint Consensus and AACE guidelines. The VAP+ utilizes direct measurement to identify cholesterol, triglyceride and genetic lipid disorders. The company’s dedication to affordable, comprehensive disease management solutions includes Our Healthy HeartTM, a patient consultation program and expert lipid management education service to health care providers. For more information, please visit www.Atherotech.com or call 1-866-VAP-TEST.


For information on Atherotech Diagnostics Lab, visit www.Atherotech.com or call 877-901-8510. Health care professionals interested in real patient cases and lipidology commentary may visit www.CobblesCorner.com, Atherotech’s official blog. Atherotech is on Twitter at www.Twitter.com/Atherotech, on Facebook at www.Facebook.com/Atherotech, and broadcasting at www.YouTube.com/user/VAPatherotech.

VAP Lipid Panel demonstrates value of cholesterol subfraction measurement in heart disease treatment and risk assessment at 2013 AHA Scientific Sessions

DALLAS — Researchers using the Atherotech VAP® Lipid Panel demonstrated the comprehensive lipid profile’s value in heart disease treatment and risk assessment. Through measurement of HDL cholesterol subfractions and remnant lipoproteins, the VAP Lipid Panel was able to identify specific lipid disorders for personalized treatment that may lead to improved outcomes in two scientific abstracts presented today at the American Heart Association (AHA) Scientific Sessions 2013 in Dallas.


The VAP Lipid Panel was utilized to measure cholesterol subfractions in Framingham Offspring Study (FOS) and Jackson Heart Study (JHS) populations, highlighting the lipid panel’s potential to improve heart disease risk reduction therapy and risk assessment compared to the standard lipid panel. In both abstracts, researchers incorporated and analyzed results for 5,932 men and women without prevalent coronary heart disease (CHD) from FOS and JHS populations, respectively, followed up over 8 years.


Abstract Poster Session 13843 (Poster 2099) — High-density Lipoprotein Cholesterol Subfractions and Risk for Cardiovascular Events in the Framingham Offspring and Jackson Heart Studies: A Meta-analysis — presented by study lead author Peter P. Toth, M.D., demonstrated that total HDL cholesterol and cholesterol subfraction HDL3, as measured by the VAP Lipid Panel, correlate highly with decreased risk for cardiovascular disease (CVD) events, while subfraction HDL2 does not.


Toth said researchers’ analysis shows that the assumptions about HDL subfractions are incorrect.


“It has been suggested based on small studies that HDL2 is protective, while HDL3 is less protective or even harmful. We show that the opposite is true, and these findings may help explain why clinical trials performed with niacin and CETP inhibitors are negative. Both of those drugs increase HDL2, a subfraction of HDL that does not correlate with cardiovascular risk,” said Toth, Director of Preventative Cardiology at CGH Medical Center in Sterling, Illinois, and a member of Atherotech’s Medical Advisory Board., who has authored or coauthored more than 200 publications and is also immediate past president of the National Lipid Association.


By combining and examining results from FOS and JHS individuals, researchers were able to quantify the relationship between HDL and its subfractions with risk for CHD-related events. Toth and coworkers showed that these results apply equally to Caucasians and African Americans enrolled in the Framingham and Jackson Heart studies, respectively.


Abstract Poster Session 14026 Poster 2100 — Remnant Lipoprotein Cholesterol Fractions and Risk for Cardiovascular Events in the Jackson Heart and Framingham Offspring Studies: A Meta-Analysis — also presented by Toth, found that cholesterol associated with intermediate density lipoprotein (IDL) and total remnant lipoprotein (RLP) correlated with a significant, increased risk for CVD events.


“This study demonstrates that VLDL remnants and intermediate-density lipoproteins contribute significantly to risk for coronary artery disease,” said Toth. Coronary artery disease is not simply attributable to elevations in LDLc alone. “These results strongly reinforce the importance of treating both LDLc and non-HDLc to risk-stratified targets.”


The relationship between RLP cholesterol and risk for CVD events was quantified by performing a meta-analysis of persons enrolled in FOS and JHS.


The patented, comprehensive VAP (Vertical Auto Profile) Lipid Panel was utilized in eight independent investigator-initiated scientific presentations at AHA 2013, including seven poster abstracts and one oral abstract. The science presented builds upon a growing body of evidence that validates the importance of accurate, affordable and comprehensive lipid risk assessment in improving outcomes and saving lives.


To arrange interviews with any of these presenters or other Atherotech medical experts who will be in attendance and can provide outside comment on these and other sessions, please call 720-231-9990 or e-mail dan@armadamedical.com. All research results are embargoed until the time they are presented during the conference. All times listed are Central Standard Time. Please refer to the American Heart Association for embargo policies pertaining to presentations at the Scientific Sessions.


The VAP Lipid Panel is covered by most insurance plans and is widely available to patients and their clinicians in the U.S. For information on the VAP Lipid Panel and Atherotech Diagnostics Lab, visit www.Atherotech.com or call 877-901-8510. Health care professionals interested in real patient cases and lipidology commentary may visit www.CobblesCorner.com, Atherotech’s official blog. Atherotech is on Twitter at www.twitter.com/Atherotech, on Facebook at www.facebook.com/Atherotech, and broadcasting at www.YouTube.com/user/VAPatherotech.


About Atherotech Diagnostics Lab & the VAP®+ Lipid Panel Atherotech Diagnostics Lab is a leading clinical reference laboratory specializing in cardiometabolic testing and disease management solutions. Atherotech’s proprietary and comprehensive VAP®+ Lipid Panel enables clinicians to accurately stratify a patient’s cardiovascular risk and deliver personalized treatment strategies to improve health outcomes. The Vertical Auto Profile (VAP+) technology reveals residual cardiometabolic risk as recommended in the NCEP ATP III, ADA/ACC Joint Consensus and AACE guidelines. The VAP+ utilizes direct measurement to identify cholesterol, triglyceride and genetic lipid disorders. The company’s dedication to affordable, comprehensive disease management solutions includes Our Healthy HeartTM, a patient consultation program and expert lipid management education service to health care providers. For more information, please visit www.Atherotech.com or call 1-866-VAP-TEST.

VAP Lipid Panel highlighted in 8 scientific presentations at 2013 American Heart Association Scientific Sessions

BIRMINGHAM, AL — The VAP® Lipid Panel from Atherotech Diagnostics Lab has been involved in numerous research projects in 2013 that support the important clinical utility of testing with the VAP Lipid Panel for comprehensive and accurate cardiovascular risk assessment.


At this year’s American Heart Association (AHA) Scientific Sessions, The VAP (Vertical Auto Profile) Lipid Panel is utilized in eight independent investigator-initiated scientific presentations: seven poster abstract presentations and one oral abstract presentation. Highly respected researchers Parag H. Joshi, M.D., Seth S. Martin, M.D., Peter P. Toth, M.D., Kristopher J. Swiger, M.D., Mohammed Al-hijji, M.D., and Raoul Manalac, M.D., are presenting findings during the conference.


Poster presentations 13843 and 14026 examine HDL subfractions, remnant lipoprotein subfractions and their relationship with cardiovascular events from a meta-analysis of the Framingham Offspring Study and Jackson Heart Study. Both will be presented from 3:00 p.m. to 4:30 p.m. on Monday, November 18, 2013, in Hall F, Core 2. Poster presentations 17313 and 17492 examine an investigational, cholesterol-lowering drug targeting the PCSK9 gene. Both will be presented on Tuesday, November 19, from 3:00 p.m. to 4:30 p.m. in Hall F, Core 2.


Three additional poster presentations — 16020, 18557, and 18730 — detail studies by Johns Hopkins researchers using Atherotech’s Very Large Database of Lipids (VLDL) and the VAP Lipid Panel. The current VLDL dataset includes more than 1.4 million data points representing unique individuals. Researchers in the VLDL presentations examined cholesterol subclasses, lipid phenotypes and the triglyceride/HDL cholesterol ratio.


Atherotech recently entered into a strategic research collaboration with the Johns Hopkins Ciccarone Center for the Prevention of Heart Disease. The partnership pairs Atherotech’s VLDL dataset with Johns Hopkins’ world-class cardiac research capabilities.


The final abstract presentation — 11909 from the Best of AHA Specialty Conferences — studies the connection between remnant lipoprotein cholesterol and mortality after acute myocardial infarction in the TRIUMPH Prospective Multi-Center Registry.


Furthermore, Atherotech will provide conference participants with their own VAP+ Lipid Panel to experience how important it is to accurately identify cardiovascular disease risk, personalize treatment and improve heart health outcomes. Atherotech representatives will be available to discuss the VAP+ Lipid Panel in booth #2308. Because LDL is directly measured, fasting is not required.


To arrange interviews with any of these presenters or other Atherotech medical experts who will be in attendance and can provide outside comment on these and other sessions, please call 720-231-9990 or e-mail dan@armadamedical.com. All research results are embargoed until the time they are presented during the conference. All times listed are Central Standard Time. Please refer to the American Heart Association for embargo policies pertaining to presentations at the Scientific Sessions.


The VAP Lipid Panel is covered by most insurance plans and is widely available to patients and their clinicians in the U.S. For information on the VAP Lipid Panel and Atherotech Diagnostics Lab, visit www.Atherotech.com or call 877-901-8510. Health care professionals interested in real patient cases and lipidology commentary may visit www.CobblesCorner.com, Atherotech’s official blog. Atherotech is on Twitter at www.twitter.com/Atherotech, on Facebook at www.facebook.com/Atherotech, and broadcasting at www.YouTube.com/user/VAPatherotech.


About Atherotech Diagnostics Lab & the VAP®+ Lipid Panel Atherotech Diagnostics Lab is a leading clinical reference laboratory specializing in cardiometabolic testing and disease management solutions. Atherotech’s proprietary and comprehensive VAP®+ Lipid Panel enables clinicians to accurately stratify a patient’s cardiovascular risk and deliver personalized treatment strategies to improve health outcomes. The Vertical Auto Profile (VAP+) technology reveals residual cardiometabolic risk as recommended in the NCEP ATP III, ADA/ACC Joint Consensus and AACE guidelines. The VAP+ utilizes direct measurement to identify cholesterol, triglyceride and genetic lipid disorders. The company’s dedication to affordable, comprehensive disease management solutions includes Our Healthy HeartTM, a patient consultation program and expert lipid management education service to health care providers. For more information, please visit www.Atherotech.com or call 1-866-VAP-TEST.

Atherotech presents latest evidence showing how comprehensive lipid testing can help improve cardiovascular disease outcomes

BIRMINGHAM, AL – New research reveals the advantages of new, more accurate risk assessment methodologies over the basic lipid panel. Atherotech Diagnostics Lab, a leading clinical reference laboratory specializing in advanced cardiometabolic testing and disease management solutions, will highlight recent evidence for improved cardiovascular disease assessment and prevention at the eighth annual Cardiometabolic Health Congress (CMHC) October 2-5, at the Sheraton Hotel in Boston.


Cardiovascular disease (CVD) remains challenging to diagnose, treat, and prevent, and large numbers of patients still do not achieve optimal control of LDLc, HDLc and triglycerides. The CMHC is one of the largest and most influential congresses dedicated to informing clinicians about the latest strategies to manage cardiometabolic disease and reduce risk.


Conference Faculty includes Atherotech Medical Advisory Board members and distinguished researchers Eliot A. Brinton, M.D., Peter McCullough, M.D., M.P.H., and Peter P. Tóth, M.D., Ph.D. The trio will present from 5:15-6:45 p.m. on October 2 during an Atherotech-sponsored symposium titled, “Advancements in Cardiometabolic Risk Assessment: Expert Analysis of Recent Evidence and Outcomes.”


“Rapidly changing demographics among U.S. patients are exacerbating critical deficiencies in traditional cardiometabolic risk assessment,” said Brinton, who currently serves as President of the American Board of Clinical Lipidology, and is also director of Atherometabolic Research at the Utah Foundation for Biomedical Research and President of the Utah Lipid Center, both in Salt Lake City. “We have known for some time that non-HDLc, apoB and LDL-P levels often add significantly to CVD risk prediction available from the traditional Friedewald-estimated LDLc. The new VAP+ is the first commercial test to measure LDL particle count directly. By including LDL-P, apoB, non-HDL-C, apoA1, and Lp(a), as well as lipoprotein subfractions, including remnant lipoproteins, the VAP+ has become the most comprehensive single lipid panel available to practicing clinicians.”


Brinton, McCullough and Tóth will review recent evidence and outcomes during Atherotech’s sponsored symposium, comparing current methodologies and their limitations to the company’s patented VAP®+ Lipid Panel, reviewing the published scientific evidence and examining the practical application of VAP+ technology with representative case studies.


As the only diagnostic assessment that captures all of the lipid information recommended in national guidelines, VAP+ measures and collates its extensive lipid-related diagnostic information into three key risk categories: Cholesterol rich, Triglyceride rich, and Hereditary factors. VAP+ measures cholesterol concentrations of all five lipoprotein classes and their subclasses, and includes the proprietary Vertical Lipoprotein Particle (VLP) technology, which allows for direct and accurate measurement of LDL particle count (LDL-P).


Data from the Atherotech VAP (Vertical Auto Profile) have been presented in numerous peer-reviewed scientific publications, including the recent Journal of the American College of Cardiology article, which highlighted that the standard estimated LDLc mis-classifies up to 60 percent of patients at highest CVD risk. This study used the Very Large Database of Lipids (VLDL), a dataset from VAP tests on more than 1.3 million blood lipid samples. Ongoing research with this VLDL dataset promises to contribute additional important insights into clinically practical methods for improving CVD risk assessment and prevention.


To attend the symposium sponsored by Atherotech Diagnostics Lab, participants must be registered attendees of the 2013 CMHC. For more information about the Cardiometabolic Health Congress and to register for the CMHC, please visit www.cardiometabolichealth.org.


For information on Atherotech Diagnostics Lab, visit www.Atherotech.com or call 877-901-8510. Health care professionals interested in real patient cases and lipidology commentary may visit www.CobblesCorner.com, Atherotech’s official blog. Atherotech is on Twitter at www.Twitter.com/Atherotech, on Facebook at www.Facebook.com/Atherotech, and broadcasting at www.YouTube.com/user/VAPatherotech.


About Atherotech Diagnostics Lab & the VAP®+ Lipid Panel Atherotech Diagnostics Lab is a leading clinical reference laboratory specializing in cardiometabolic testing and disease management solutions. Atherotech’s proprietary and comprehensive VAP®+ Lipid Panel enables clinicians to accurately stratify a patient’s cardiovascular risk and deliver personalized treatment strategies to improve health outcomes. The Vertical Auto Profile (VAP+) technology reveals residual cardiometabolic risk as recommended in the NCEP ATP III, ADA/ACC Joint Consensus and AACE guidelines. The VAP+ utilizes direct measurement to identify cholesterol, triglyceride and genetic lipid disorders. The company’s dedication to affordable, comprehensive disease management solutions includes Our Healthy HeartTM, a patient consultation program and expert lipid management education service to health care providers. For more information, please visit www.Atherotech.com or call 1-866-VAP-TEST.

Atherotech bolsters research efforts with addition of Abate as Chief Clinical Officer

BIRMINGHAM, ALAtherotech Diagnostics Lab, a leading clinical reference laboratory specializing in cardiometabolic testing and disease management solutions, announces the addition of Gerard Abate, M.D., as the company’s Chief Clinical Officer.


Abate is responsible for expanding awareness of the company’s patented VAP+® Lipid Panel and its clinical utility in cardiometabolic research. He will work with Atherotech’s distinguished Medical Advisory Board and field of Medical Science Consultants to help clinicians better understand cardiovascular risk reduction and deliver personalized treatment strategies to improve health outcomes.


“Jerry has vast experience in developing strategic relationships with key thought leaders in academics as well as relationships with key medical societies,” CEO Michael Mullen said. “He understands the power of preventive cardiovascular medicine and the role it plays in accurately stratifying risk.”


Abate spent 14 years as a non-invasive clinical cardiologist and owner of Williamsburg Cardiology in Williamsburg, Va. As a specialist in consultative cardiology focused on heart failure and lipidology, he became an early adopter in the utilization of advanced lipid assessments.


In 2004, Abate left his practice for work in the pharmaceutical industry supporting various cardiovascular products. He most recently served as Senior Medical Director for Thrombosis in Medical Affairs at Daiichi Sankyo. He played a key role in the development and execution of the medical strategy for the upcoming launch of Daiichi Sankyo’s oral anticoagulant edoxaban and oversaw the communications and clinical trial strategy for the company’s Effient antiplatelet agent.


Throughout his career in the pharmaceutical industry, Abate brought forth product advancements and process improvements to the medical affairs departments he worked in. He was instrumental in revising the investigator-initiated trial process at Sanofi Aventis and brought automation to several companies, improving efficiency, compliance and controlling budgets. During his time with Amarin Pharma Inc., he built all medical affairs functions and was responsible for the startup of the 8,000-patient REDUCE-IT cardiovascular outcomes trial for the drug Vascepa®.


“Jerry will foster our relationships within the pharmaceutical industry as well as lead our strategic research collaborations, including the recent partnership with Johns Hopkins Ciccarone Center for the Prevention of Heart Disease,” Mullen said. “He brings the energy and intelligence that are instrumental in keeping the momentum in these latest research initiatives.”


For information on Atherotech Diagnostics Lab, visit www.Atherotech.com or call 877-901-8510. Health care professionals interested in real patient cases and lipidology commentary may visit www.CobblesCorner.com, Atherotech’s official blog. Atherotech is on Twitter at www.Twitter.com/Atherotech, on Facebook at www.Facebook.com/Atherotech, and broadcasting at www.YouTube.com/user/VAPatherotech.


About Atherotech Diagnostics Lab & the VAP®+ Lipid Panel
Atherotech Diagnostics Lab is a leading clinical reference laboratory specializing in cardiometabolic testing and disease management solutions. Atherotech’s proprietary and comprehensive VAP®+ Lipid Panel enables clinicians to accurately stratify a patient’s cardiovascular risk and deliver personalized treatment strategies to improve health outcomes. The Vertical Auto Profile (VAP+) technology reveals residual cardiometabolic risk as recommended in the NCEP ATP III, ADA/ACC Joint Consensus and AACE guidelines. The VAP+ utilizes direct measurement to identify cholesterol, triglyceride and genetic lipid disorders. The company’s dedication to affordable, comprehensive disease management solutions includes Our Healthy HeartTM, a patient consultation program and expert lipid management education service to health care providers. For more information, please visit www.Atherotech.com or call 1-866-VAP-TEST.